ZA200802632B - 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors - Google Patents

3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors

Info

Publication number
ZA200802632B
ZA200802632B ZA200802632A ZA200802632A ZA200802632B ZA 200802632 B ZA200802632 B ZA 200802632B ZA 200802632 A ZA200802632 A ZA 200802632A ZA 200802632 A ZA200802632 A ZA 200802632A ZA 200802632 B ZA200802632 B ZA 200802632B
Authority
ZA
South Africa
Prior art keywords
alkyl
tetrahydrofutran
pyrrolidin
intermediates
oxo
Prior art date
Application number
ZA200802632A
Other languages
English (en)
Inventor
Sedelmeier Gottfried
Grimler Dominique
Acemoglu Murat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200802632(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200802632B publication Critical patent/ZA200802632B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA200802632A 2005-10-17 2008-03-25 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors ZA200802632B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0521083.6A GB0521083D0 (en) 2005-10-17 2005-10-17 Organic compounds

Publications (1)

Publication Number Publication Date
ZA200802632B true ZA200802632B (en) 2009-04-29

Family

ID=35451886

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802632A ZA200802632B (en) 2005-10-17 2008-03-25 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors

Country Status (30)

Country Link
US (2) US7772405B2 (es)
EP (1) EP1948643B1 (es)
JP (3) JP5356031B2 (es)
KR (1) KR101294432B1 (es)
CN (2) CN103121995B (es)
AR (1) AR058089A1 (es)
AU (1) AU2006303489B2 (es)
BR (1) BRPI0617492A2 (es)
CA (2) CA2829487A1 (es)
CY (1) CY1114308T1 (es)
DK (1) DK1948643T3 (es)
EC (1) ECSP088368A (es)
ES (1) ES2427098T3 (es)
GB (1) GB0521083D0 (es)
HK (1) HK1120509A1 (es)
HR (1) HRP20130793T1 (es)
IL (1) IL190330A (es)
JO (1) JO2926B1 (es)
MY (1) MY145466A (es)
NO (1) NO342854B1 (es)
NZ (1) NZ567042A (es)
PE (2) PE20120581A1 (es)
PL (1) PL1948643T3 (es)
PT (1) PT1948643E (es)
RU (1) RU2432354C2 (es)
SI (1) SI1948643T1 (es)
TN (1) TNSN08170A1 (es)
TW (1) TWI395733B (es)
WO (1) WO2007045420A2 (es)
ZA (1) ZA200802632B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
DE102005052195A1 (de) * 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
CN101679213A (zh) * 2007-04-03 2010-03-24 诺瓦提斯公司 新方法
RU2010101236A (ru) * 2007-06-19 2011-07-27 Новартис АГ (CH) Органические соединения
DE102007049039A1 (de) * 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
SI2189442T1 (sl) * 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
WO2011019789A1 (en) 2009-08-11 2011-02-17 Novartis Ag The ring opening of lactones and lactams
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
CN101774986B (zh) * 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
CN102485722B (zh) * 2010-12-06 2014-05-07 博瑞生物医药技术(苏州)有限公司 阿利克仑、其中间体和药用盐及制备方法
CN102775393B (zh) * 2011-05-09 2014-08-27 上海现代制药股份有限公司 一种药物中间体的制备方法
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
CN102746182B (zh) * 2012-07-27 2014-09-03 浙江普洛医药科技有限公司 一种阿利克伦的制备方法
CN103059012B (zh) * 2013-01-30 2016-06-22 浙江海翔药业股份有限公司 1,8-二羰基-4,5-环氧化合物及其制备方法
CN106220528B (zh) * 2014-02-28 2018-05-08 华润双鹤药业股份有限公司 阿利吉仑的4-位差向异构体、其制备方法及用途
CN105294612A (zh) * 2014-06-05 2016-02-03 山东威智医药工业有限公司 阿利克仑中间体及其制备方法和应用
US10087190B1 (en) * 2017-04-24 2018-10-02 Purdue Research Foundation Lactones
CN114315749B (zh) * 2021-12-13 2024-04-26 湖南华腾医药有限公司 一种连续流微反应器合成阿利克仑中间体的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP1200390B1 (de) 1999-07-29 2008-08-27 Speedel Pharma AG Herstellung von n-substituierten 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamiden
FR2801051B1 (fr) * 1999-11-17 2001-12-14 Adir Nouveaux composes aminopyrroline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6310904B1 (en) 2000-05-31 2001-10-30 Honeywell International, Inc. Measurement method to facilitate production of self-aligning laser gyroscope block
DE60123911T2 (de) 2000-12-14 2007-05-31 Speedel Pharma Ag Verfahren zur Herstellung von Aryloctanoyl-amiden
KR100903228B1 (ko) * 2001-09-07 2009-06-17 바스프 에스이 2-피롤리돈의 제조 방법
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
EP1689702B1 (en) * 2003-11-26 2013-01-30 Novartis AG Organic compounds
BRPI0417543A (pt) * 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
PT1717226E (pt) * 2004-03-19 2009-04-03 Novartis Ag Derivados de 5-amino-4-hidroxi-8-(1h-indol-5-il)-octan amida 2,7-substituída como inibidores da renina para o tratamento da hipertensão
EP1582523A1 (en) * 2004-04-02 2005-10-05 Ludwig-Maximilians-Universität München Method of preparing organomagnesium compounds
GB0419361D0 (en) * 2004-08-31 2004-10-06 Novartis Ag Organic compounds
GB0511686D0 (en) 2005-06-08 2005-07-13 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
RU2008119276A (ru) 2009-11-27
MY145466A (en) 2012-02-15
NO20082263L (no) 2008-07-07
KR101294432B1 (ko) 2013-08-07
CN101111493B (zh) 2013-02-13
JO2926B1 (en) 2015-09-15
ES2427098T3 (es) 2013-10-28
CY1114308T1 (el) 2016-08-31
NO342854B1 (no) 2018-08-20
WO2007045420A2 (en) 2007-04-26
US8198465B2 (en) 2012-06-12
CN103121995A (zh) 2013-05-29
JP2013032369A (ja) 2013-02-14
AU2006303489B2 (en) 2011-04-07
CA2625034A1 (en) 2007-04-26
IL190330A (en) 2013-12-31
PL1948643T3 (pl) 2013-11-29
CA2625034C (en) 2014-08-19
JP2009514808A (ja) 2009-04-09
JP5356031B2 (ja) 2013-12-04
TW200800965A (en) 2008-01-01
JP2014196312A (ja) 2014-10-16
CN103121995B (zh) 2016-08-03
SI1948643T1 (sl) 2013-10-30
DK1948643T3 (da) 2013-09-08
PE20120581A1 (es) 2012-06-08
CA2829487A1 (en) 2007-04-26
BRPI0617492A2 (pt) 2011-07-26
GB0521083D0 (en) 2005-11-23
AU2006303489A1 (en) 2007-04-26
IL190330A0 (en) 2009-09-22
PT1948643E (pt) 2013-09-05
HK1120509A1 (en) 2009-04-03
PE20070792A1 (es) 2007-09-10
US20100267965A1 (en) 2010-10-21
US7772405B2 (en) 2010-08-10
HRP20130793T1 (hr) 2013-09-30
ECSP088368A (es) 2008-05-30
EP1948643A2 (en) 2008-07-30
TWI395733B (zh) 2013-05-11
JP5792139B2 (ja) 2015-10-07
KR20080057285A (ko) 2008-06-24
EP1948643B1 (en) 2013-06-05
AR058089A1 (es) 2008-01-23
WO2007045420A3 (en) 2007-06-07
NZ567042A (en) 2012-02-24
RU2432354C2 (ru) 2011-10-27
TNSN08170A1 (en) 2009-10-30
US20080262246A1 (en) 2008-10-23
CN101111493A (zh) 2008-01-23

Similar Documents

Publication Publication Date Title
HRP20130793T1 (hr) Derivati 3-alkil-5-(4-alkil-5-okso-tetrahidrofuran-2-il)pirolidin-2-ona kao meä�uprodukti u sintezi inhibitora renina
IL184303A0 (en) Amino-pyridines as inhibitors of ??-secretase
TWI347321B (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL180242A0 (en) Piperidine derivatives as renin inhibitors
HK1107348A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL190077A0 (en) Pyrrolopyrimidine derivatives as syk inhibitors
IL185185A0 (en) Azolylacylguanidines as ??-secretase inhibitors
IL178100A0 (en) 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
IL189048A (en) Uranium derivatives as 3-gsk inhibitors
EP1957474A4 (en) SYNTHESIS OF FTFZ INHIBITORS
IL185769A0 (en) Heterocyclic-substituted alkanamides useful as renin inhibitors
EP1910272A4 (en) INHIBITORS OF THE RENINE
ZA200803030B (en) Pyrrolopyrimidine derivatives as Syk inhibitors
EP1889619A4 (en) USE OF COMPOUNDS OF THIADIAZOLIDINE AS NEUROGENE AGENTS
EP1891003A4 (en) FLUORALKYLAMINE DERIVATIVES AS CATHEPSIN INHIBITORS
ZA200808598B (en) Pyrrolopyrimidine derivatives used as HSP90 inhibitors
ZA200710338B (en) Oxydiazole derivatives as DGAT inhibitors
AU2005906584A0 (en) Use of Inhibitors of Prolyl-4-Hydroxylases
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors